The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
about
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysPersistent infection of macaques with simian-human immunodeficiency virusesSimian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysAbility of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4CKR-L3, a deletion version CCR6-isoform shows coreceptor-activity for limited human and simian immunodeficiency viruses.Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization.Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence of differential selection of RP-specific envelope mutations in vitro and in vivoCCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses.Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5.Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virusMolecular and biological analyses of quasispecies during evolution of a virulent simian immunodeficiency virus, SIVsmmPBj14.Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5)An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeysA chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys.Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysStudies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinSpontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus.Extensive envelope heterogeneity of simian immunodeficiency virus in tissues from infected macaques.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.A simian immunodeficiency virus envelope V3 cytotoxic T-lymphocyte epitope in rhesus monkeys and its restricting major histocompatibility complex class I molecule Mamu-A*02.Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.Simian immunodeficiency viruses from central and western Africa: evidence for a new species-specific lentivirus in tantalus monkeys.Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loopProbing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domainsImportance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development.Animal models in virus research: their utility and limitations.Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoproteinCharacterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein
P2860
Q28751926-A310960A-F2F7-4F31-9A2E-E2C6514EDE49Q28775731-6F93EAA0-9C59-4E85-AF6A-9459CD71B475Q32157141-E2D16107-CE08-4824-8356-70F1423698C1Q33649657-65F4EC1F-4FF1-4A46-AFA5-2222D66F9822Q33785114-E72EA98C-9833-43B7-91EC-B8641A357DE1Q33851405-BE4D7DB2-A513-4BA3-96BB-31EE0978BF13Q33872944-9CCF37F9-C626-4FE0-A1DE-BC2E84B83D43Q33873610-A31FDEEA-28C2-4EE6-AE66-CF845E93B88CQ34302179-9DC172E8-BA3C-47D0-8827-75844A5BB10AQ34979722-8BE96C7A-B7A1-407C-B9F6-2779152F9168Q34996824-3C268E53-D547-4762-80D6-0132AC8089F7Q35833044-189BBDD5-BF38-4CE6-B517-42986CCF0FC4Q35837061-4CF2C9F7-47D3-49BA-B381-4907674E0D75Q35839457-060EF090-A131-4133-8277-5BB4C21886FBQ35848231-95F7E193-B3B4-43AE-9368-392D8750CFB7Q35848683-BB452AEC-2BF9-4DDD-A73A-B896C470E9AFQ35860563-37FCCD54-A174-41A1-9BE0-CBA356F29880Q35870467-200544F9-B3D4-44D0-AE82-4EFCD04AF939Q35871440-2322DA13-C70A-4E29-8783-AE0C579BEF0DQ35879871-70084FD6-B887-46D2-98A8-CA754E16862FQ35885915-78FBA1D9-5850-4E26-AAA5-E1FC0804FF89Q35896178-C575FFA7-5FEE-4241-BD4A-C948A4B29A0CQ35955770-7F220706-5E3F-438D-BF3C-D0F29CF8B3E5Q36155555-04F42923-E809-42CD-B6A8-53D605BB8776Q36632605-97D94EE8-4C11-4AB7-AB9D-1AD7EB5C6BCFQ36632673-F72066D3-183E-4E96-B66C-C62CCA4DDB9CQ36633502-F436BA0D-F298-4DE2-8932-A4CB6F4417EBQ36634149-465DCC81-C81F-4384-805C-C92D7F88CA99Q36634778-1D53D378-DD48-4E29-9752-27CF7B1DE94CQ36636293-C5CD58A3-2CE9-4584-8BA2-5ACD60C7619AQ36636482-24E28A2B-F5BE-4D3A-B3F6-721204E8B1D6Q36640342-02BCF731-AC37-4F71-8589-22717E768E42Q36642795-EEF870AE-C849-4B5D-A6D5-977108082F17Q36651187-74FD4A3C-425F-485C-A3BB-C99DFFE666F2Q36653730-201B95BC-3E31-457E-B520-48327835162BQ36949880-DBA95A12-8D7B-4CA7-AD91-D190D8F40F40Q37316026-ED0D70C0-99EA-4D02-B3E1-8937A5D05EADQ38043556-7E85D9B0-6626-46B6-8B9E-A86A725E7380Q39591825-2BA1B215-3BB4-434A-8413-AEBAEF202FE1Q39592994-DD10A429-97AF-434D-9DC3-BB3E4028C8C6
P2860
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The principal neutralization d ...... immunodeficiency virus type 1.
@en
type
label
The principal neutralization d ...... immunodeficiency virus type 1.
@en
prefLabel
The principal neutralization d ...... immunodeficiency virus type 1.
@en
P2093
P2860
P356
P1476
The principal neutralization d ...... immunodeficiency virus type 1.
@en
P2093
A J Langlois
D P Bolognesi
J P Langedijk
K Javaherian
M Kaufmann
R C Desrosiers
R H Meloen
P2860
P304
P356
10.1073/PNAS.89.4.1418
P407
P577
1992-02-01T00:00:00Z